EN

Enzo Biochem IncNYSE ENZ Stock Report

Last reporting period 31 Oct, 2024

Updated 20 Dec, 2024

Last price

Market cap $B

0.058

Micro

Exchange

XNYS - New York Stock Exchange, Inc

ENZ Stock Analysis

EN

Uncovered

Enzo Biochem Inc is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

-35/100

Low score

Market cap $B

0.058

Dividend yield

8.77 %

Shares outstanding

49.663 B

Enzo Biochem, Inc. is an integrated diagnostics, clinical lab, and life sciences company, which focuses on delivering and applying advanced technology capabilities to produce affordable reliable products and services that enable customers to meet their clinical needs. The company is headquartered in Farmingdale, New York and currently employs 465 full-time employees. The firm is focused on delivering and applying advanced technology capabilities to produce products and services that enable its customers to meet their clinical needs. The firm operates through three segments. Enzo Clinical Lab segment is a clinical reference laboratory, which provides a range of clinical services to physicians, medical centers, other clinical labs and pharmaceutical companies. Enzo Life Sciences segment manufactures, develops and markets products and tools for clinical research, drug development and bioscience research customers worldwide. Enzo Life Sciences has developed products used in the identification of genomic information by laboratories around the world. Enzo Therapeutics is a biopharmaceutical venture that has developed multiple approaches in the areas of gastrointestinal, infectious, ophthalmic and metabolic diseases.

View Section: Eyestock Rating